Comerica Bank Raises Position in Integra Lifesciences Holdings Corp (IART)

Comerica Bank increased its stake in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 2.6% in the 1st quarter, Holdings Channel reports. The firm owned 48,508 shares of the life sciences company’s stock after buying an additional 1,239 shares during the quarter. Comerica Bank’s holdings in Integra Lifesciences were worth $2,649,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of IART. Oregon Public Employees Retirement Fund raised its position in shares of Integra Lifesciences by 4,410.0% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,254,051 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 1,226,245 shares during the last quarter. Brown Advisory Inc. acquired a new position in Integra Lifesciences in the 4th quarter valued at $45,653,000. Norges Bank acquired a new position in Integra Lifesciences in the 4th quarter valued at $32,141,000. Janus Henderson Group PLC raised its holdings in Integra Lifesciences by 31.5% in the 1st quarter. Janus Henderson Group PLC now owns 2,873,324 shares of the life sciences company’s stock valued at $160,102,000 after acquiring an additional 688,761 shares during the last quarter. Finally, Vaughan Nelson Investment Management L.P. raised its holdings in Integra Lifesciences by 138.5% in the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 880,167 shares of the life sciences company’s stock valued at $39,695,000 after acquiring an additional 511,085 shares during the last quarter. Hedge funds and other institutional investors own 84.29% of the company’s stock.

In other news, insider Lisa Evoli sold 1,291 shares of the business’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $55.90, for a total transaction of $72,166.90. Following the completion of the sale, the insider now directly owns 4,968 shares of the company’s stock, valued at approximately $277,711.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Christian S. Schade sold 15,658 shares of the business’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $51.56, for a total transaction of $807,326.48. The disclosure for this sale can be found here. Insiders have sold a total of 47,077 shares of company stock valued at $2,568,469 over the last three months. Corporate insiders own 4.50% of the company’s stock.

Several brokerages have weighed in on IART. Cantor Fitzgerald reiterated a “hold” rating and issued a $50.00 price target on shares of Integra Lifesciences in a report on Thursday, February 21st. BidaskClub downgraded Integra Lifesciences from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. Oppenheimer cut their price target on Integra Lifesciences from $70.00 to $65.00 and set an “outperform” rating for the company in a report on Thursday, April 25th. ValuEngine downgraded Integra Lifesciences from a “hold” rating to a “sell” rating in a report on Thursday, April 18th. Finally, Zacks Investment Research upgraded Integra Lifesciences from a “hold” rating to a “buy” rating and set a $59.00 price target for the company in a report on Thursday, May 9th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $58.91.

Shares of NASDAQ IART opened at $49.76 on Thursday. Integra Lifesciences Holdings Corp has a 52-week low of $42.14 and a 52-week high of $67.50. The firm has a market cap of $4.25 billion, a PE ratio of 20.56, a P/E/G ratio of 1.43 and a beta of 0.90. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.86 and a quick ratio of 1.86.

Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings data on Wednesday, April 24th. The life sciences company reported $0.65 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.61 by $0.04. Integra Lifesciences had a net margin of 5.60% and a return on equity of 15.60%. The company had revenue of $359.69 million during the quarter, compared to analysts’ expectations of $361.12 million. During the same period in the previous year, the company earned $0.58 EPS. The business’s quarterly revenue was up .7% compared to the same quarter last year. As a group, sell-side analysts expect that Integra Lifesciences Holdings Corp will post 2.7 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Comerica Bank Raises Position in Integra Lifesciences Holdings Corp (IART)” was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.baseballdailydigest.com/news/2019/05/23/comerica-bank-raises-position-in-integra-lifesciences-holdings-corp-iart.html.

Integra Lifesciences Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Further Reading: What are Institutional Investors?

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.